7-OH and Kratom Are Pharmacologically Distinct: New Review Finds Concentrated 7-Hydroxymitragynine Products Pose Significant Opioid-Like Risks

Why it matters

This comprehensive review clarifies that 7-OH products are chemically and pharmacologically distinct from traditional kratom leaf, with opioid potency exceeding morphine. Clinicians and policymakers need this distinction to make evidence-based decisions on regulation.

The big picture

Kratom leaf has been used traditionally for centuries with minimal 7-OH exposure. However, U.S. market products increasingly feature chemically enriched or semi-synthetic 7-OH with potent opioid-like effects. The review synthesizes pharmacological, toxicological, and clinical evidence showing 7-OH behaves as a strong mu-opioid agonist with documented risks of dependence, respiratory depression, and death—distinct from whole-leaf kratom.

Key findings

• 7-hydroxymitragynine is a partial μ-opioid receptor agonist with nanomolar affinity and greater efficacy than mitragynine, often exceeding morphine potency
• Concentrated 7-OH products bypass metabolic formation, producing markedly higher systemic exposures than kratom leaf
• Animal and human data document robust opioid-like effects: antinociception, respiratory depression, tolerance, dependence, and reinforcing properties
• State health departments have reported severe intoxications and fatalities linked to 7-OH products
• Pediatric risk is amplified by developmental susceptibility, absence of age restrictions, and marketing in confectionary formats

What they say

Collectively, the evidence demonstrates that concentrated 7-OH products are pharmacologically and toxicologically distinct from kratom leaf and pose significant risks of morbidity and mortality under typical conditions of use.

Bottom line

**7-OH products are not kratom—they are semi-synthetic opioids requiring distinct regulatory and clinical approaches from botanical kratom leaf.**